On February 5, 2014, the HHS Office of Inspector General (OIG) released a report on the 340B drug discount program and the use of contract pharmacies in that program. This report is the result of Congressional inquiry into the oversight of the 340B program, especially with the recent growth in the program. The report looked at contract pharmacy arrangements for covered entities, specifically the policies on preventing duplicate discounts and diversion. While the report did not make any formal recommendations, it found that there is a lack of clarity in current requirements for the program and noted that it will continue to review these arrangements and may issue additional reports on the subject. HRSA released a memo in response to the report, reminding covered entities of their responsibilities with regards to contract pharmacy. You can read a summary of the report here or the report itself here.
We will continue to keep you updated on the latest developments with regards to 340B.